The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Year: 2002
Type: review
Study design: Systematic Review
Abstract: CostsAn incremental economic analysis was undertaken to estimate the additional costs and quality-adjusted life-year (QALY) gains associated with the use of either etanercept or infliximab, either as the third DMARD in a sequence of DMARDs or separately as last-resort therapy (i.e.used last in a DMARD sequence).A simulation model was constructed that considered improvements in quality of life but assumed no effect of either etanercept or infliximab on mortality or the need for joint replacement.For use as the third DMARD in a sequence of DMARDs, the Birmingham Preliminary Model gave a base-case incremental cost-effectiveness ratio of approximately £83,000 per QALY for etanercept and approximately £115,000 per QALY for infliximab.These figures reduced to £72,000 per QALY for etanercept, and £95,000 for infliximab, if they were used last in the sequence of DMARDs.Sensitivity analysis in the latter case gave figures ranging from £47,000 to £128,000 for etanercept and £62,000 to £169,000 for infliximab.It should be stressed that these figures do not include all benefits.Further research is needed on the effect of all DMARDs on joint replacement, hospitalisation, mortality and quality of life.the American Rheumatism Association (ARA) in 1987, are shown in Table 1.6 These criteria were derived from a group of typical patients who had been diagnosed with RA and had well-established
Source: Health Technology Assessment
DOI: 10.3310/hta6210
Authors: P. Jobanputra, P. Barton, S. Bryan, A. Burls
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G1572554084, G4314261081
OpenAlex ID: W2097585904